TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Identifieur interne : 000288 ( PubMed/Checkpoint ); précédent : 000287; suivant : 000289TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Auteurs : Dandan Wu [République populaire de Chine] ; Xuexian O. Yang [États-Unis]Source :
- Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [ 1995-9133 ] ; 2020.
Abstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
DOI: 10.1016/j.jmii.2020.03.005
PubMed: 32205092
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32205092Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.</title><author><name sortKey="Wu, Dandan" sort="Wu, Dandan" uniqKey="Wu D" first="Dandan" last="Wu">Dandan Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128</wicri:regionArea><wicri:noRegion>410128</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Xuexian O" sort="Yang, Xuexian O" uniqKey="Yang X" first="Xuexian O" last="Yang">Xuexian O. Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA. Electronic address: xyang@salud.unm.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131</wicri:regionArea><wicri:noRegion>87131</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32205092</idno><idno type="pmid">32205092</idno><idno type="doi">10.1016/j.jmii.2020.03.005</idno><idno type="wicri:Area/PubMed/Corpus">000069</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000069</idno><idno type="wicri:Area/PubMed/Curation">000069</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000069</idno><idno type="wicri:Area/PubMed/Checkpoint">000288</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000288</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.</title><author><name sortKey="Wu, Dandan" sort="Wu, Dandan" uniqKey="Wu D" first="Dandan" last="Wu">Dandan Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128</wicri:regionArea><wicri:noRegion>410128</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Xuexian O" sort="Yang, Xuexian O" uniqKey="Yang X" first="Xuexian O" last="Yang">Xuexian O. Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA. Electronic address: xyang@salud.unm.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131</wicri:regionArea><wicri:noRegion>87131</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</title><idno type="eISSN">1995-9133</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32205092</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-9133</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</Title><ISOAbbreviation>J Microbiol Immunol Infect</ISOAbbreviation></Journal><ArticleTitle>TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1684-1182(20)30065-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmii.2020.03.005</ELocationID><Abstract><AbstractText>COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xuexian O</ForeName><Initials>XO</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA. Electronic address: xyang@salud.unm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Microbiol Immunol Infect</MedlineTA><NlmUniqueID>100956211</NlmUniqueID><ISSNLinking>1684-1182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine storm</Keyword><Keyword MajorTopicYN="N">JAK2 inhibitor</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TH17</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest All authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId><ArticleId IdType="pii">S1684-1182(20)30065-7</ArticleId><ArticleId IdType="doi">10.1016/j.jmii.2020.03.005</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Wu, Dandan" sort="Wu, Dandan" uniqKey="Wu D" first="Dandan" last="Wu">Dandan Wu</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Yang, Xuexian O" sort="Yang, Xuexian O" uniqKey="Yang X" first="Xuexian O" last="Yang">Xuexian O. Yang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000288 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000288 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32205092
|texte= TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32205092" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |